Menu
Search
|

Menu

Close
X

Agile Therapeutics Inc AGRX.OQ (NASDAQ Stock Exchange Global Market)

3.69 USD
+0.04 (+1.10%)
As of Feb 16
chart
Previous Close 3.65
Open 3.65
Volume 34,244
3m Avg Volume 66,654
Today’s High 3.72
Today’s Low 3.60
52 Week High 5.59
52 Week Low 1.93
Shares Outstanding (mil) 34.19
Market Capitalization (mil) 126.15
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.742
FY16
-1.018
FY15
-1.381
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
--
8.57
Price to Book (MRQ)
vs sector
3.03
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
29.06
15.12
LT Debt to Equity (MRQ)
vs sector
14.16
11.85
Return on Investment (TTM)
vs sector
-51.35
13.54
Return on Equity (TTM)
vs sector
-61.80
14.80

EXECUTIVE LEADERSHIP

Alfred Altomari
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $362,500.00
Bonus: $160,000.00
Scott Coiante
Chief Financial Officer, Vice President, Since 2011
Salary: $250,000.00
Bonus: $76,300.00
Elizabeth Garner
Senior Vice President, Chief Medical Officer, Since 2014
Salary: $315,960.00
Bonus: $108,000.00
Renee Selman
Chief Commercial Officer, Since 2016
Salary: --
Bonus: --
Abhijeet Lele
Lead Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

101 Poor Farm Rd
PRINCETON   NJ   08540-1941

Phone: +1609.6831880

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

SPONSORED STORIES